You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆指觸及萬八關後遇壓 醫藥板塊發力漲逾3%-9%
市場對聯儲局下月再加息預期降溫。此外,據報中國政府正考慮增加2023年預算赤字,併發行1萬億元人民幣債務,以支持經濟實現國家增長目標。港股連升第五天,恆指今早在新經濟股及權重金融股主導高開292點或近1.7%報17,956,最多升347點或1.9%報18,012,現報17,900,續升236點點或1.3%,總成交額388億元。 醫藥板塊今早全面發力跑贏大市,康希諾(06185.HK)股價曾一舉重越50天及100天線(25元及26.5元),最多急漲12.6%高見26.8元遇壓,現報26元,回升9.2%;康希諾A(688185.SH)漲6.8%報83.7元人民幣。 騰盛博藥-B(02137.HK)升破20天線,最高見2.8元,現報2.58元,升8.4%。康方生物-B(09926.HK)回升7%曾高見39.35元,股價重越250天線(38.17元)。信達生物(01801.HK)最高見42.8元創近半年高,現報42.05元,回升6.2%。君實生物(01877.HK)升破20天線,最高見18.8元,現報18.48元,回升7.7%。開拓-B(09939.HK)升破20天線,最高見3.13元,現報2.86元,回升6.3%。 藍籌中生(01177.HK)/石藥(01093.HK)、金斯瑞生物(01548.HK)、藥明康德(02359.HK)、聯邦製藥(03933.HK)及藍籌藥明生物(02269.HK)升逾3.5%-6%,後兩者最強,股價曾分別高見8.09元及48.25元(暫受制250天線48.8元),現報7.98元及47.65元,齊升6.5%。 科濟藥業-B(02171.HK)、諾誠健華-B(09969.HK)、和鉑醫藥-B(2142.HK)及百濟神州(06160.HK)升逾4%-6.5%,後者跑贏,股價升破10天線,最高見112.3元,現報111.4元,回升6.5%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account